| Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial N Dizman, L Meza, P Bergerot, M Alcantara, T Dorff, Y Lyou, P Frankel, ... Nature medicine 28 (4), 704-712, 2022 | 225 | 2022 |
| Metastasis in renal cell carcinoma: Biology and implications for therapy J Gong, MC Maia, N Dizman, A Govindarajan, SK Pal Asian journal of urology 3 (4), 286-292, 2016 | 148 | 2016 |
| Stool microbiome profiling of patients with metastatic renal cell carcinoma receiving anti–PD-1 immune checkpoint inhibitors NJ Salgia, PG Bergerot, MC Maia, N Dizman, JA Hsu, JD Gillece, ... European urology 78 (4), 498-502, 2020 | 129 | 2020 |
| Genomic profiling in renal cell carcinoma N Dizman, EJ Philip, SK Pal Nature Reviews Nephrology 16 (8), 435-451, 2020 | 114 | 2020 |
| Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors C Casadei, N Dizman, G Schepisi, MC Cursano, U Basso, D Santini, ... Therapeutic advances in medical oncology 11, 1758835919890285, 2019 | 90 | 2019 |
| First-line immuno-oncology combination therapies in metastatic renal-cell carcinoma: results from the international metastatic renal-cell carcinoma database consortium S Dudani, J Graham, JC Wells, Z Bakouny, SK Pal, N Dizman, F Donskov, ... European urology 76 (6), 861-867, 2019 | 79 | 2019 |
| Responses to alectinib in ALK-rearranged papillary renal cell carcinoma SK Pal, P Bergerot, N Dizman, C Bergerot, J Adashek, R Madison, ... Eur Urol 74 (1), 124-128, 2018 | 69 | 2018 |
| Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell‐free DNA results SK Pal, D Bajorin, N Dizman, J Hoffman‐Censits, DI Quinn, DP Petrylak, ... Cancer 126 (11), 2597-2606, 2020 | 50 | 2020 |
| Association of circulating tumor DNA (ctDNA) detection in metastatic renal cell carcinoma (mRCC) with tumor burden MC Maia, PG Bergerot, N Dizman, JA Hsu, J Jones, RB Lanman, ... Kidney Cancer 1 (1), 65-70, 2017 | 43 | 2017 |
| Randomized trial assessing impact of probiotic supplementation on gut microbiome and clinical outcome from targeted therapy in metastatic renal cell carcinoma N Dizman, JA Hsu, PG Bergerot, JD Gillece, M Folkerts, L Reining, J Trent, ... Cancer Medicine 10 (1), 79-86, 2021 | 42 | 2021 |
| Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis N Dizman, Y Lyou, N Salgia, PG Bergerot, JA Hsu, D Enriquez, T Izatt, ... Journal for immunotherapy of cancer 8 (2), 2020 | 34 | 2020 |
| Assessment of distress and quality of life in rare cancers CD Bergerot, PG Bergerot, EJ Philip, EBL De Domenico, MFM Manhaes, ... Psycho‐Oncology 27 (12), 2740-2746, 2018 | 32 | 2018 |
| Examining public communication about kidney cancer on Twitter MS Sedrak, MM Salgia, C Decat Bergerot, K Ashing-Giwa, BN Cotta, ... JCO Clinical Cancer Informatics 3, 1-6, 2019 | 30 | 2019 |
| Cancer therapy targeting CD47/SIRPα N Dizman, EI Buchbinder Cancers 13 (24), 6229, 2021 | 28 | 2021 |
| Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma A Chehrazi-Raffle, L Meza, M Alcantara, N Dizman, P Bergerot, N Salgia, ... Journal for Immunotherapy of Cancer 9 (3), 2021 | 27 | 2021 |
| Discrepancies between genitourinary cancer patients' and clinicians' characterization of the Eastern Cooperative Oncology Group performance status CD Bergerot, EJ Philip, PG Bergerot, JA Hsu, N Dizman, M Salgia, ... Cancer 127 (3), 354-358, 2021 | 26 | 2021 |
| Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy ML Baker, Y Yamamoto, MA Perazella, N Dizman, AC Shirali, N Hafez, ... Journal for immunotherapy of cancer 10 (3), 2022 | 25 | 2022 |
| Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic … CL Gan, S Dudani, JC Wells, F Donskov, SK Pal, N Dizman, N Rathi, ... Cancer medicine 10 (4), 1212-1221, 2021 | 25 | 2021 |
| Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy CD Bergerot, PG Bergerot, EJ Philip, JA Hsu, N Dizman, U Vaishampayan, ... Journal for ImmunoTherapy of Cancer 7, 1-5, 2019 | 24 | 2019 |
| Relationship of tumor mutational burden (TMB) to immunotherapy response in metastatic renal cell carcinoma (mRCC). MC Maia, L Almeida, PG Bergerot, N Dizman, SK Pal Journal of Clinical Oncology 36 (6_suppl), 662-662, 2018 | 22 | 2018 |
Sumanta PalCity of HopeVerified email at coh.org
